Corneal chemical burn treatment through a delivery system consisting of TGF-β1 siRNA: in vitro and in vivo

Drug Deliv Transl Res. 2018 Oct;8(5):1127-1138. doi: 10.1007/s13346-018-0546-0.

Abstract

Chemical burns are major causes of corneal blindness. Transforming growth factor beta-1 (TGFβ1) plays an important role in induction of corneal inflammation-related-fibrosis leading to the blindness. Here, a topical delivery system consisting anti-fibrotic TGF-β1 siRNA, an inflammatory suppressing gene, was designed for treatment of corneal injuries. TGF-β1 siRNA loaded in nanoparticles (NPs) made up of polyethyleneimine polymer demonstrated high fibroblast transfection efficiency. Moreover, TGF-β1 and PDGF genes and ECM deposition were suppressed in isolated human corneal fibroblasts. NPs inhibited proliferation and transformation of fibroblasts to myofibroblasts by S-phase arrest and α-SMA suppression in vitro, respectively. The mentioned finding was also confirmed in vivo, addressing high wound-healing potential of prepared gene delivery system which was superior to conventional betamethasone treatment. Besides, CD4+ and α-SMA antibody staining showed inhibited angiogenesis and myofibroblast accumulation in treated corneas. This study opens a new way for treating corneal fibrosis through topical siRNA delivery.

Keywords: Angiogenesis; Corneal haze; Myofibroblasts; Polyethyleneimine; TGF-β1 siRNA.

MeSH terms

  • Administration, Topical
  • Animals
  • Burns, Chemical / drug therapy*
  • Burns, Chemical / metabolism
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cornea / cytology*
  • Cornea / drug effects
  • Disease Models, Animal
  • Eye Burns / drug therapy*
  • Eye Burns / metabolism
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Gene Expression Regulation / drug effects
  • Humans
  • Male
  • Mice
  • Nanoparticles
  • Platelet-Derived Growth Factor / metabolism
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / pharmacology
  • Transforming Growth Factor beta1 / antagonists & inhibitors*

Substances

  • Platelet-Derived Growth Factor
  • RNA, Small Interfering
  • Transforming Growth Factor beta1